X4 Pharmaceuticals (XFOR) Price & Analysis

Compare

1,104 Followers

XFOR Stock Chart & Stats

$3.75

-$0.07(-10.26%)

At close: Jan 08 4:00 PM EST

$3.75

-$0.07(-10.26%)

Day’s Range― - ―

52-Week Range$1.35 - $26.84

Previous CloseN/A

Volume769.31K

Average Volume (3M)1.30M

Market Cap

$327.89M

Enterprise Value$102.93M

Total Cash (Recent Filing)$122.42M

Total Debt (Recent Filing)$77.36M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Mar 12, 2026

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.69

Shares Outstanding87,436,690

10 Day Avg. Volume485,031

30 Day Avg. Volume1,295,474

Financial Highlights & Ratios

PEG Ratio0.06

Price to Book (P/B)6.66

Price to Sales (P/S)57.69

P/FCF Ratio-1.12

Enterprise Value/Market Cap0.31

Enterprise Value/Revenue3.03

Enterprise Value/Gross Profit3.64

Enterprise Value/Ebitda-1.22

Forecast

1Y Price Target

$6.25

Price Target Upside66.67% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-2.13

Revenue Forecast (FY)$34.51M

Bulls Say, Bears Say

Bulls Say

Corporate RestructuringThe company executed a corporate restructuring to ensure long-term growth, including a major overhaul of the executive suite.

Financial StrengthThe company fortified its balance sheet with a secondary offering and a private placement, resulting in total gross proceeds of $240.3M, providing an operational runway well beyond the date when results of Study 4WARD could be released.

Leadership And ManagementThe appointment of new C-suite management and board of directors, including experienced leaders from CTI BioPharma, is expected to strengthen X4 Pharmaceuticals' position.

Bears Say

Financial Performance3Q25 GAAP net loss was wider than both the analyst's and consensus estimates.

Revenue DeclineTotal revenue of $1.8M was down 10% sequentially and below the analyst's and consensus estimates.

X4 Pharmaceuticals News

X4 Pharmaceuticals price target raised to $5 from $3.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on X4 Pharmaceuticals (XFOR) to $5 from $3.50 and keeps a...

13d ago

XFOR

X4 Pharmaceuticals price target lowered to $7.50 from $9 at Stifel

Stifel lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $7.50 from $9 and keeps a Buy...

18d ago

XFOR

X4 Pharmaceuticals reports Q3 EPS (69c), consensus (84c)

Reports Q3 revenue $199,000, consensus $1.9M. “The third quarter of 2025 was a time of corporate restructuring at...

18d ago

XFOR

X4 Pharmaceuticals Focuses on Chronic Neutropenia Trial

X4 Pharmaceuticals ( ($XFOR) ) has released its Q3 earnings. Here is a breakdown of the information X4...

17d ago

XFOR

X4 Pharmaceuticals 45.87M share Spot Secondary priced at $2.85

The deal range was $2.85-$2.95. Leerink, Stifel and Guggenheim acted as joint book running managers for the offering....

1M ago

XFOR

X4 Pharmaceuticals announces common stock offering, no amount given

X4 Pharmaceuticals (XFOR) announced that it has commenced an underwritten public offering of shares of its common stock...

1M ago

XFOR

Altimmune appoints Christophe Arbet-Engels as CMO

Altimmune (ALT) announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025....

2M ago

ALT

XFOR

X4 Pharmaceuticals Announces Major Strategic Restructuring

X4 Pharmaceuticals ( ($XFOR) ) has provided an update. On September 17, 2025, X4 Pharmaceuticals announced a strategic...

2M ago

XFOR

X4 Pharmaceuticals announces restructuring, 50% reduction in workforce

X4 Pharmaceuticals (XFOR) announced a strategic restructuring designed to sharpen operational focus and align resources with the Company’s...

2M ago

XFOR

X4 Pharmaceuticals files to sell 59.89M shares of common stock for holders

16:17 EDT X4 Pharmaceuticals (XFOR) files to sell 59.89M shares of common stock for holders Published first on...

2M ago

XFOR

X4 Pharmaceuticals price target lowered to $9 from $30 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on X4 Pharmaceuticals (XFOR) to $9 from $30 and...

3M ago

XFOR

X4 Pharmaceuticals Announces Board Resignations and Appointments

The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On August 22, 2025, X4 Pharmaceuticals, Inc....

3M ago

XFOR

3 Penny Stocks to Watch Now, 8/14/25

Momentus, X4 Pharmaceuticals, and ReShape Lifesciences are the 3 Penny Stocks to watch on August 14, 2025, based on TipRanks’ Penny...

3M ago

MNTS

RSLS

X4 Pharmaceuticals Closes $85M Private Placement Deal

The latest announcement is out from X4 Pharmaceuticals ( ($XFOR) ). On August 13, 2025, X4 Pharmaceuticals announced...

3M ago

XFOR

XFOR FAQ

What was X4 Pharmaceuticals Inc’s price range in the past 12 months?

X4 Pharmaceuticals Inc lowest stock price was $1.35 and its highest was $26.84 in the past 12 months.

What is X4 Pharmaceuticals Inc’s market cap?

X4 Pharmaceuticals Inc’s market cap is $327.89M.

When is X4 Pharmaceuticals Inc’s upcoming earnings report date?

X4 Pharmaceuticals Inc’s upcoming earnings report date is Mar 12, 2026 which is in 109 days.

How were X4 Pharmaceuticals Inc’s earnings last quarter?

X4 Pharmaceuticals Inc released its earnings results on Nov 05, 2025. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.505 by -$0.185.

Is X4 Pharmaceuticals Inc overvalued?

According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does X4 Pharmaceuticals Inc pay dividends?

X4 Pharmaceuticals Inc does not currently pay dividends.

What is X4 Pharmaceuticals Inc’s EPS estimate?

X4 Pharmaceuticals Inc’s EPS estimate is -0.26.

How many shares outstanding does X4 Pharmaceuticals Inc have?

X4 Pharmaceuticals Inc has 87,436,690 shares outstanding.

What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?

X4 Pharmaceuticals Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.505. Following the earnings report the stock price went down -10.579%.

Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in XFOR

X4 Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-156.87%

Trailing 12-Months

Asset Growth

-8.20%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals (XFOR) Earnings & Revenues

Historic Earnings Reports

XFOR Stock 12 Month Forecast

Average Price Target

$6.25

▲(66.67% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","43":"$43","10.75":"$10.75","21.5":"$21.5","32.25":"$32.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,10.75,21.5,32.25,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.306153846153846,4.572307692307692,4.838461538461538,5.104615384615385,5.3707692307692305,5.636923076923077,5.903076923076923,6.169230769230769,6.435384615384615,6.701538461538462,6.967692307692308,7.233846153846153,{"y":7.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.21,4.38,4.55,4.72,4.89,5.0600000000000005,5.23,5.4,5.57,5.74,5.91,6.08,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.113846153846154,4.187692307692307,4.2615384615384615,4.335384615384616,4.409230769230769,4.483076923076923,4.556923076923077,4.63076923076923,4.704615384615384,4.7784615384615385,4.852307692307692,4.926153846153846,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.3,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.15,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.3,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.57,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >